4 Managing suspected or confirmed pneumonia
4.1 Be aware that older people, or those with comorbidities, frailty, impaired immunity or a reduced ability to cough and clear secretions, are more likely to develop severe pneumonia. Because this can lead to respiratory failure and death, hospital admission would have been the usual recommendation for these people before the COVID‑19 pandemic.
4.2 When making decisions about hospital admission, take into account:
the severity of the pneumonia, including symptoms and signs of more severe illness (see recommendation 3.4)
the benefits, risks and disadvantages of hospital admission
the care that can be offered in hospital compared with at home
the patient's wishes and care plans (see the section on treatment and care planning)
service delivery issues and local NHS resources during the COVID‑19 pandemic.
4.3 Explain that:
the benefits of hospital admission include improved diagnostic tests (chest X-ray, microbiological tests and blood tests) and respiratory support
the risks and disadvantages of hospital admission include spreading or catching COVID‑19 and loss of contact with families.
4.4 Be aware that severe breathlessness often causes anxiety, which can then increase breathlessness further. See the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community for advice on how to manage breathlessness.
4.5 As COVID‑19 pneumonia is caused by a virus, antibiotics are ineffective.
4.6 Do not offer an antibiotic for treatment or prevention of pneumonia if:
COVID‑19 is likely to be the cause and
symptoms are mild.
Inappropriate antibiotic use may reduce availability if used indiscriminately, and broad-spectrum antibiotics in particular may lead to Clostridioides difficile infection and antimicrobial resistance.
4.7 Offer an oral antibiotic for treatment of pneumonia in people who can or wish to be treated in the community if:
the likely cause is bacterial or
it is unclear whether the cause is bacterial or viral and symptoms are more concerning or
they are at high risk of complications because, for example, they are older or frail, or have a pre-existing comorbidity such as immunosuppression or significant heart or lung disease (for example bronchiectasis or COPD), or have a history of severe illness following previous lung infection.
4.8 When starting antibiotic treatment, the first-choice oral antibiotic is:
doxycycline 200 mg on the first day, then 100 mg once a day for 4 days (5-day course in total); doxycycline should not be used in pregnancy
alternative: amoxicillin 500 mg 3 times a day for 5 days.
Doxycycline is preferred because it has a broader spectrum of cover than amoxicillin, particularly against Mycoplasma pneumoniae and Staphylococcus aureus, which are more likely to be secondary bacterial causes of pneumonia during the COVID-19 pandemic. [amended 23 April 2020]
4.9 Do not routinely use dual antibiotics.
4.10 For choice of antibiotics in penicillin allergy, pregnancy and more severe disease, or if atypical pathogens are likely, see the recommendations on choice of antibiotic in the NICE antimicrobial prescribing guideline on community-acquired pneumonia.
4.11 Start antibiotic treatment as soon as possible, taking into account any different methods needed to deliver medicines to patients during the COVID‑19 pandemic (see recommendation 1.3).
4.12 Do not routinely offer a corticosteroid unless the patient has other conditions for which these are indicated, such as asthma or COPD.
4.13 Advise patients to seek medical help without delay if their symptoms do not improve as expected or worsen rapidly or significantly, whether they are taking an antibiotic or not (see recommendation 1.1 and recommendation 3.4).